> Research Use Only (RUO) Disclaimer: This guide describes dulaglutide dosing and protocols as documented in peer-reviewed clinical literature and FDA-approved prescribing information (Trulicity® package insert). It is provided for educational and research purposes only. Dulaglutide (Trulicity®) is an FDA-regulated prescription medication. Any use outside of a licensed medical or institutional research setting may be illegal. Consult a qualified healthcare professional before using any pharmaceutical compound.
Dulaglutide, marketed as Trulicity® by Eli Lilly, is one of the most widely prescribed once-weekly GLP-1 receptor agonists globally. Since its FDA approval in 2014, the drug has expanded from two dose strengths (0.75 mg and 1.5 mg) to four (adding 3.0 mg and 4.5 mg in 2020), providing researchers and clinicians with a broad therapeutic window for metabolic and cardiovascular endpoint studies.
This guide consolidates the AWARD trial dosing data, injection administration protocols, GI management strategies, and comparative clinical data to support informed research decision-making.
---
What Is Dulaglutide?
Dulaglutide is a once-weekly subcutaneous GLP-1 receptor agonist engineered as an Fc fusion protein — a human GLP-1 analog (90% homology) linked to a modified human IgG4 Fc fragment. This architecture extends the half-life to approximately 5 days, enabling weekly dosing compared to the daily injections required for liraglutide.
Key pharmacological features:
- •Mechanism: GLP-1 receptor agonist — stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying
- •Half-life: ~5 days (enables once-weekly dosing)
- •Tmax: 24–72 hours post-injection (median 48 hours)
- •Steady state: Achieved within 2–4 weeks of once-weekly dosing
- •Renal elimination: Not the primary elimination pathway; no dose adjustment needed for renal impairment
- •FDA indications: Type 2 diabetes mellitus (glycemic control) + cardiovascular risk reduction in adults with established CV disease or multiple CV risk factors
---
FDA-Approved Dose Strengths
Dulaglutide is available in four presentations, all as single-dose autoinjector pens and single-use prefilled syringes:
| Dose | Pen Color | Primary Research Context |
|---|---|---|
| 0.75 mg/0.5 mL | Gray cap | Starting dose; GI tolerance establishment |
| 1.5 mg/0.5 mL | Blue cap | Standard therapeutic target (AWARD-1 through -8 primary endpoint) |
| 3.0 mg/0.5 mL | Purple cap | Higher-dose option; AWARD-11 superior HbA1c arm |
| 4.5 mg/0.5 mL | Red cap | Maximum dose; AWARD-11 highest HbA1c reduction arm |
No reconstitution is required. Dulaglutide pens come prefilled with a clear, colorless, sterile, preservative-free solution ready for subcutaneous injection. Unlike lyophilized peptides that require reconstitution with bacteriostatic water, dulaglutide arrives in a ready-to-use format — verify the solution is clear and colorless before each use. Do not use if particulate matter or discoloration is present.
---
Dose Escalation Protocol
The AWARD clinical trial program established a stepped escalation protocol based on 4-week intervals, allowing gastrointestinal adaptation at each dose level before advancing.
Standard 4-Step Escalation Schedule
| Phase | Weeks | Dose | Notes |
|---|---|---|---|
| Initiation | Weeks 1–4 | 0.75 mg once weekly | GI tolerance establishment |
| Step 1 | Weeks 5–8 | 1.5 mg once weekly | Primary therapeutic target for most subjects |
| Step 2 (optional) | Weeks 9–12 | 3.0 mg once weekly | For additional glycemic response |
| Step 3 (optional) | Weeks 13+ | 4.5 mg once weekly | Maximum approved dose |
Escalation decision criteria from AWARD trials:
- •Advance only if GI side effects (nausea, vomiting, diarrhea) have subsided at the current dose
- •The 4-week window at each level allows GLP-1 receptor downregulation of emetic pathways
- •If GI intolerance persists at any step, hold the current dose for an additional 4 weeks before advancing or consider whether higher dosing is appropriate for the research protocol
Conservative Approach (For GI-Sensitive Subjects)
Some research protocols have explored an 8-week dwell period at each dose:
| Phase | Duration | Dose |
|---|---|---|
| Initiation | 8 weeks | 0.75 mg |
| Standard | 8 weeks | 1.5 mg |
| High dose (if needed) | 8+ weeks | 3.0 mg |
This conservative approach prioritizes tolerability and is associated with improved subject retention in longer studies.
---
AWARD Trial Dosing Data
The AWARD (Assessment of Weekly Administration of dulaglutide in Diabetes) program comprises 11+ Phase 3 trials that established the clinical evidence base for all four dose strengths.
Key AWARD Efficacy Data
AWARD-11 (n=1,842; 52 weeks) — The pivotal trial for 3.0 mg and 4.5 mg approval:
- •Mean baseline HbA1c: 8.6%; Mean baseline BMI: 34.2 kg/m²
- •Dulaglutide 4.5 mg: HbA1c reduction −1.87% vs. −1.54% for 1.5 mg (superior, p<0.001)
- •Dulaglutide 3.0 mg: HbA1c reduction −1.73% (superior, p<0.001)
- •Weight loss at 52 weeks: −4.7 kg (4.5 mg) vs. −3.1 kg (1.5 mg)
AWARD-1 through AWARD-8 (0.75 mg and 1.5 mg, head-to-head comparisons):
- •HbA1c reductions ranged from −0.7% to −1.9% depending on dose and background therapy
- •1.5 mg consistently demonstrated non-inferiority or superiority vs. sitagliptin, exenatide BID, and insulin glargine
Cardiovascular Outcomes (REWIND Trial, n=9,901)
- •5.4-year median follow-up; primary MACE reduction: 12% vs. placebo (HR 0.88, 95% CI 0.79–0.99)
- •Notably, ~69% of REWIND participants had no prior CV event — broader at-risk population than many CV outcomes trials
---
Injection Site Administration
Approved Injection Sites
Dulaglutide is administered via subcutaneous injection at three sites:
| Site | Location | Notes |
|---|---|---|
| Abdomen | At least 5 cm from navel | Most commonly used; easiest self-injection |
| Thigh | Front or outer area | Avoid inner thigh |
| Upper arm | Outer/posterior area | May require caregiver assistance for self-injection |
Injection site pharmacokinetics: Subcutaneous administration site (abdomen, upper arm, or thigh) has no statistically significant effect on dulaglutide exposure — confirmed by population PK analysis.
Injection Technique
1. Remove pen from refrigerator 30 minutes before injection (room temperature reduces injection discomfort)
2. Inspect pen — solution should be clear and colorless
3. Select and clean injection site with alcohol swab; allow to dry
4. Remove gray base cap (and then clear cap if applicable)
5. Place pen flat against skin at the chosen site
6. Press and hold the green injection button until two clicks are heard (injection complete)
7. Hold pen in place for 5–10 seconds after second click
8. Rotate injection site with each weekly dose to prevent lipohypertrophy
Administration Timing
- •Once weekly — any time of day, with or without food
- •Day flexibility: The weekly administration day can be changed if the last dose was administered ≥3 days (72 hours) before the new scheduled day
- •Missed dose: If ≥72 hours remain until the next scheduled dose, administer the missed dose immediately. If <72 hours remain, skip and resume the regular schedule. Never double-dose.
- •Insulin co-administration: Inject separately; do not mix in the same syringe. Adjacent anatomical regions are acceptable but not immediately adjacent injection points.
---
GI Management and Titration Strategy
Gastrointestinal side effects — nausea, vomiting, diarrhea, dyspepsia — are the most common adverse events across all GLP-1 receptor agonists and drove the graduated 4-week escalation schedule.
GI Incidence by Dose (AWARD-11, 52 weeks)
| Adverse Event | 1.5 mg | 3.0 mg | 4.5 mg |
|---|---|---|---|
| Nausea | 20% | 26% | 28% |
| Diarrhea | 13% | 17% | 17% |
| Vomiting | 11% | 17% | 18% |
| Abdominal pain | 9% | 10% | 10% |
Temporal pattern: GI events peak in the first 2–8 weeks and are predominantly transient. Most subjects who tolerate 1.5 mg successfully have dramatically lower GI event rates at higher doses than treatment-naive initiation.
Practical Mitigation Strategies
- •Dietary: Avoid high-fat, high-calorie meals on injection day and the following 24–48 hours
- •Hydration: Maintain adequate fluid intake; dehydration exacerbates nausea
- •Meal size: Smaller, more frequent meals during the first weeks at each new dose level
- •Injection timing: Some subjects report better GI tolerance when injecting before the largest meal of the day (though food timing does not affect pharmacokinetics)
- •Anti-emetics: Ondansetron or ginger supplementation may be considered per research protocol for subjects with persistent nausea; document use in study notes
---
Storage and Handling
Storage Requirements
| Condition | Temperature | Duration |
|---|---|---|
| Primary storage | 2°C to 8°C (36–46°F) — refrigerated | Until expiration date |
| Room temperature | ≤30°C (86°F) | Up to 14 days |
Critical handling notes:
- •Do not freeze — freezing denatures the Fc fusion protein; discard if frozen
- •Protect from light — store in original carton until time of use
- •After 14 days at room temperature — discard; do not return to refrigerator
- •Visual inspection: Clear, colorless, no particulate matter required before each use
- •Single-dose only — the pen is designed for a single injection; discard after use
Unlike lyophilized peptide powders, dulaglutide requires no reconstitution. This significantly simplifies research logistics compared to compounds like semaglutide (oral), gonadorelin, or peptides requiring bacteriostatic water preparation. The pre-filled pen format minimizes preparation error and maintains sterility.
---
Comparison with GLP-1 RA Class (Research Context)
Understanding dulaglutide's position within the GLP-1 receptor agonist class helps contextualize research protocol selection:
Head-to-Head Research Data Summary
| Metric | Liraglutide (daily) | Dulaglutide (weekly) | Semaglutide sc (weekly) |
|---|---|---|---|
| Mean weight loss | ~2.81 kg | ~4.03 kg | ~4.81 kg |
| HbA1c reduction | Moderate | Good | Superior |
| Dosing frequency | Daily | Once weekly | Once weekly |
| CV outcomes data | LEADER (positive) | REWIND (positive) | SUSTAIN-6 (positive) |
| Reconstitution | Not required | Not required | Not required |
Key comparative findings (2024 meta-analysis, PMC12120964):
- •Semaglutide demonstrates superior HbA1c reduction vs. dulaglutide (SMD 3.72, p=0.05) and superior weight loss (~4.81 vs. ~4.03 kg)
- •Dulaglutide provides better HbA1c reduction than liraglutide
- •Dulaglutide offers weekly vs. daily administration advantage over liraglutide
- •Tirzepatide (dual GIP/GLP-1) outperforms all three in both endpoints
Practical research selection considerations:
- •Dulaglutide is preferred when weekly dosing convenience is required and weight loss is not the primary endpoint
- •Semaglutide is selected for maximum weight loss or HbA1c reduction studies
- •Liraglutide remains relevant for daily injection studies or established comparison datasets
For detailed semaglutide and liraglutide dosing protocols, see our companion guides:
- •Semaglutide Dosage Guide: Research Protocol & Reconstitution (2026)
- •Liraglutide Dosage Guide: Research Protocol & Timing (2026)
- •GLP-1 Receptor Agonists: Complete Research Overview
---
Dulaglutide Research Profile & Background
For full mechanistic detail, pharmacokinetics, and the REWIND cardiovascular data, see the companion article:
That profile covers:
- •Fc fusion engineering rationale (IgG4 vs. IgG1 modifications)
- •Complete pharmacokinetic parameter table
- •REWIND trial design and subgroup analyses
- •Mechanism of action at the GLP-1 receptor
- •Regulatory history and label evolution (2014–2026)
---
Supplier Availability
Dulaglutide (Trulicity) is an FDA-regulated prescription medication. As of current data, no verified research-grade suppliers are listed in the Peptides.SO database for this compound. Given the FDA shortage status of 0.75 mg and 1.5 mg strengths (as of late 2024), availability through standard pharmaceutical channels may be limited.
Researchers sourcing dulaglutide for institutional studies should coordinate with their institutional pharmacy or licensed pharmaceutical distributor. The 503B outsourcing facility provisions issued during the shortage period may provide alternative sourcing options for research institutions — consult with a licensed compounding pharmacist and institutional review board regarding sourcing compliance.
---
Key Takeaways for Research Protocols
1. Start at 0.75 mg — mandatory GI tolerance step; never initiate at higher doses
2. 4-week intervals between dose escalations — mirror AWARD-11 protocol for data comparability
3. No reconstitution required — significant research logistics advantage over lyophilized peptides
4. Refrigerate; 14-day room temp maximum — critical for compound integrity
5. Rotate injection sites — prevents lipohypertrophy that can alter absorption kinetics
6. Weekly flexibility — dose day can shift if ≥72 hours maintained; suitable for subject scheduling
7. Superior to liraglutide in HbA1c reduction; inferior to semaglutide in weight loss and HbA1c
8. REWIND CV data makes dulaglutide relevant for cardiovascular endpoint research
9. Document GI events — use standardized scales (GIQLI or GSRS) for adverse event capture
10. No dose adjustment for renal impairment — broadens eligible research population
---
> Disclaimer: This article is for research and educational purposes only. Dulaglutide (Trulicity®) is a prescription medication approved by the FDA for type 2 diabetes and cardiovascular risk reduction. This content does not constitute medical advice, diagnosis, or treatment recommendation. Peptides.SO is a research information platform; all peptide and pharmaceutical information provided is intended for licensed researchers, medical professionals, and institutional review. Always comply with all applicable laws, regulations, and institutional protocols when working with pharmaceutical compounds.